(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Astrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's ...

This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...

An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...

An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...

Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...

AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

Scientists from the University of Sheffield and AstraZeneca have created an AI approach that could make designing proteins ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Virtual. About Innate Pharma. Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunothera ...